0000-00-00 |
|
|
|
External link to document |
2019-04-30 |
1 |
Complaint |
“Roche Patents”); and
• U.S. Patents Nos. 7,915,225 (“the ’225 Patent”), 8,119,605…United States Patent Nos. 8,063,182 (“the ’182 Patent”), 8,163,522 (“the ’522 Patent”),
7,915,225 (“the ’225…arthritis. The ’225 Patent, the ’605 Patent, and the ’631 Patent (“the Immunex Patents”), owned
by Immunex…States Patent Nos. 8,063,182 (“the ’182 Patent”) and 8,163,522
(“the ’522 Patent”) (collectively… Patent”), and 8,722,631 (“the ’631 Patent”) (collectively, “the Immunex Patents”).
|
External link to document |
2019-12-22 |
107 |
Amended Complaint |
Immunopathology and Immunity, 4' Edition,
6,201,105 B1 3, 2001 Smith et al. …activities”, Eur, J. Immunol. 20:1167-1174
6,201,105 B1 3, 2001 Smith et al. … U.S. Patent No. 8,063,182 (“the ’182 Patent”),
• U.S. Patent No. 8,163,…Roche Patents”),
• U.S. Patent No. 6,872,549 (“the ’549 Patent”),
… U.S. Patent No. 6,924,124 (“the ’124 Patent”),
• U.S. Patent No. 7,157, |
External link to document |
2019-08-05 |
70 |
Answer to Complaint |
. 7,915,225 (“the ’225 patent”), 8,119,605 (“the ’605 patent), and
8,722,631 (“the ’631 patent) (collectively…the “Roche Patents”); and
• U.S. Patents Nos. 7,915,225 (“the ’225 Patent”), 8,119,…the ’522 Patent”); 7,915,225 (“the ’225
Patent”); 8,119,605 (“the ’605 Patent”); and 8,722,631 (“the ’…products: U.S. Patent Nos. 8,063,182 (“the ’182 patent”); 8,163,522 (“the ’522 patent”);
7,915,225; 8,119,605… States Patent Nos. 8,063,182 (“the ’182 Patent”), 8,163,522 (“the ’522 Patent”),
7,915,225 (“the ’225 |
External link to document |